MedPath

Embark Early Education Ltd

Embark Early Education Ltd logo
🇩🇪Germany
Ownership
Public
Established
1993-01-01
Employees
5.1K
Market Cap
$1.3B
Website
http://evotec.com
Introduction

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

manilatimes.net
·

QUANTRO Therapeutics achieves breakthrough in drug discovery for cancer and inflammation

QUANTRO Therapeutics completed a 10-target multiplex-screening campaign, advancing drug discovery for cancer and inflammation. CEO Dr. Michael Bauer will attend Biotech Showcase and WuXi Global Forum in San Francisco, Jan 13-16, 2025, to discuss QUANTRO's innovative transcriptomic drug discovery platform and seek partnerships.
eqs-news.com
·

QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery

QUANTRO Therapeutics achieves a breakthrough in transcriptomic drug discovery with its first successful 10-target multiplex-screening, enhancing its QUANTROseq® platform's capability to discover novel therapies for cancer and inflammation. CEO Dr. Michael Bauer will present these advancements at the Biotech Showcase and WuXi Global Forum in January 2025.

QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening

QUANTRO Therapeutics completed a 10-target multiplex-screening campaign, advancing its QUANTROseq® platform for cancer and inflammation treatments. CEO Dr. Michael Bauer will attend Biotech Showcase and WuXi Global Forum in San Francisco to discuss innovations and seek partnerships.

QUANTRO Therapeutics GmbH: QUANTRO Therapeutics reaches a milestone with Boehringer Ingelheim in developing first-in-class cancer treatments

QUANTRO Therapeutics achieved a milestone with Boehringer Ingelheim in developing first-in-class cancer treatments, successfully applying QUANTROseq® technology to identify high-quality hits for undruggable transcription factors, aiming to transform cancer treatment options.
finance.yahoo.com
·

QUANTRO Therapeutics achieves breakthrough in transcriptomic drug development

QUANTRO Therapeutics completed a 10-target multiplex-screening campaign, advancing its QUANTROseq® platform for novel cancer and inflammation treatments. CEO Dr. Michael Bauer will attend Biotech Showcase and WuXi Global Forum in San Francisco to discuss innovations and seek partnerships.
globenewswire.com
·

QUANTRO Therapeutics achieves breakthrough in novel cancer and inflammation treatments

QUANTRO Therapeutics completed a 10-target multiplex-screening campaign, advancing its QUANTROseq® platform for novel cancer and inflammation treatments. CEO Dr. Michael Bauer will attend Biotech Showcase and WuXi Global Forum in San Francisco to discuss transcriptomic drug discovery and seek partnerships.
pharmaphorum.com
·

GSK to accelerate drug discovery with artificial intelligence company

GlaxoSmithKline partners with Exscientia, leveraging AI to expedite drug discovery, aiming to reduce time and cost by 75%. The collaboration targets novel small molecules for up to 10 diseases, with GSK paying £33 million upon achieving milestones. Exscientia's AI platform, combining big data and experienced drug developers, automates drug design, promising faster, cost-effective discovery without compromising quality.
biospace.com
·

Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C FDA Meeting

Kazia Therapeutics updated on paxalisib's regulatory pathway for glioblastoma treatment after a Type C FDA meeting. FDA suggested OS data supports standard, not accelerated, approval. Kazia plans a pivotal Phase 3 study, aligning with FDA on design. Paxalisib also shows promise in pediatric brain cancer and breast cancer treatments.
bionity.com
·

QUANTRO Therapeutics GmbH - Wien, Austria

QUANTRO Therapeutics, a spin-off from IMBA and IMP in Vienna, focuses on discovering therapeutics targeting disease-causing transcriptional programs, especially in cancer, using innovative drug-discovery methods like time-resolved RNA sequencing. Supported by Boehringer Ingelheim Venture Fund and Evotec.
© Copyright 2025. All Rights Reserved by MedPath